CO2020003424A2 - Cristal - Google Patents

Cristal

Info

Publication number
CO2020003424A2
CO2020003424A2 CONC2020/0003424A CO2020003424A CO2020003424A2 CO 2020003424 A2 CO2020003424 A2 CO 2020003424A2 CO 2020003424 A CO2020003424 A CO 2020003424A CO 2020003424 A2 CO2020003424 A2 CO 2020003424A2
Authority
CO
Colombia
Prior art keywords
crystal
referred
diphenylpyrazin
butyloxy
isopropylamino
Prior art date
Application number
CONC2020/0003424A
Other languages
English (en)
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of CO2020003424A2 publication Critical patent/CO2020003424A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Un objeto principal de la presente invención consiste en proporcionar un nuevo cristal de ácido 2–{4–[N–(5,6–difenilpirazin–2–il)–N–isopropilamino]butiloxi}acético (de ahora en más en la presente, mencionado como “compuesto B”).
CONC2020/0003424A 2017-09-28 2020-03-24 Cristal CO2020003424A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017187296 2017-09-28
PCT/JP2018/035828 WO2019065792A1 (ja) 2017-09-28 2018-09-27 結晶

Publications (1)

Publication Number Publication Date
CO2020003424A2 true CO2020003424A2 (es) 2020-06-19

Family

ID=65902864

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0003424A CO2020003424A2 (es) 2017-09-28 2020-03-24 Cristal

Country Status (18)

Country Link
US (3) US10906879B2 (es)
EP (2) EP3689854A4 (es)
JP (3) JP7160043B2 (es)
KR (2) KR20240042215A (es)
CN (2) CN117510418A (es)
AR (1) AR112842A1 (es)
AU (2) AU2018338856B2 (es)
BR (1) BR112020005428A2 (es)
CA (1) CA3076877A1 (es)
CO (1) CO2020003424A2 (es)
IL (1) IL273430A (es)
MX (2) MX2020007315A (es)
PH (1) PH12020550149A1 (es)
RU (1) RU2020112117A (es)
SG (1) SG11202002443QA (es)
TW (2) TWI801421B (es)
UA (1) UA126928C2 (es)
WO (1) WO2019065792A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117510418A (zh) * 2017-09-28 2024-02-06 日本新药株式会社 结晶
WO2021023271A1 (zh) * 2019-08-06 2021-02-11 南京明德新药研发有限公司 作为前列环素受体激动剂的化合物的晶型及其制备方法
US20220281830A1 (en) * 2019-08-19 2022-09-08 Nippon Shinyaku Co., Ltd. Salt

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (es) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
JP5522030B2 (ja) 2008-02-28 2014-06-18 日本新薬株式会社 線維化抑制剤
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
SI2292231T1 (sl) 2008-06-23 2016-03-31 Nippon Shinyaku Co., Ltd. Terapevtsko sredstvo za stenozo spinalnega kanala
KR101639821B1 (ko) 2008-06-23 2016-07-14 니뽄 신야쿠 가부시키가이샤 염증성 장질환 치료제
MX2011000897A (es) 2008-07-23 2011-03-30 Toray Industries Agente terapeutico para falla renal cronica.
BR122021005510B1 (pt) 2009-06-26 2022-01-11 Nippon Shinyaku Co., Ltd Forma ii do cristal de 2-{4-[n-(5,6-difenilpirazin-2-il)-n isopropilamino]butilóxi}-n- metilsulfonil)acetamida e composição farmacêutica
CN106279047B (zh) * 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 一种前列环素受体激动剂的制备方法
WO2017042828A2 (en) * 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Process for the preparation of selexipag and intermediates thereof
WO2017060827A1 (en) * 2015-10-07 2017-04-13 Lupin Limited An imrpoved process for the preparation of selexipag or its pharmaceutically acceptable salts
WO2018008042A1 (en) 2016-07-05 2018-01-11 Maithri Drugs Private Limited Novel process for the preparation of 2-{4-[(5,6-diphenyl pyrazin-2-yl)(isopropyl)amino]butoxy}-n-(methylsulfonyl)acetamide and novel polymorphs thereof
CN106957269A (zh) 2016-12-21 2017-07-18 南京艾德凯腾生物医药有限责任公司 一种成人肺动脉高压治疗药物赛乐西帕的制备方法
CN107365275B (zh) * 2017-06-14 2020-07-03 杭州华东医药集团新药研究院有限公司 高纯度的赛乐西帕
CN117510418A (zh) * 2017-09-28 2024-02-06 日本新药株式会社 结晶

Also Published As

Publication number Publication date
JP2022173401A (ja) 2022-11-18
KR20240042215A (ko) 2024-04-01
TW201920121A (zh) 2019-06-01
AU2018338856B2 (en) 2023-09-21
US20230303500A1 (en) 2023-09-28
SG11202002443QA (en) 2020-04-29
IL273430A (en) 2020-05-31
CN111263754A (zh) 2020-06-09
US20210114995A1 (en) 2021-04-22
EP3689854A4 (en) 2021-06-09
AU2023274142A1 (en) 2023-12-21
MX2020007315A (es) 2020-08-20
JP7485738B2 (ja) 2024-05-16
TW202332673A (zh) 2023-08-16
MX2023004668A (es) 2023-05-19
TWI801421B (zh) 2023-05-11
JPWO2019065792A1 (ja) 2020-10-22
RU2020112117A (ru) 2021-10-28
AR112842A1 (es) 2019-12-18
PH12020550149A1 (en) 2021-02-08
US11655218B2 (en) 2023-05-23
US20200223804A1 (en) 2020-07-16
AU2018338856A1 (en) 2020-04-16
UA126928C2 (uk) 2023-02-22
BR112020005428A2 (pt) 2020-09-29
US10906879B2 (en) 2021-02-02
KR102675320B1 (ko) 2024-06-14
WO2019065792A1 (ja) 2019-04-04
EP4371617A2 (en) 2024-05-22
CA3076877A1 (en) 2019-04-04
JP2024045685A (ja) 2024-04-02
TWI834536B (zh) 2024-03-01
CN117510418A (zh) 2024-02-06
JP7160043B2 (ja) 2022-10-25
EP3689854A1 (en) 2020-08-05
KR20200060393A (ko) 2020-05-29

Similar Documents

Publication Publication Date Title
CO2020003424A2 (es) Cristal
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
IN2015MN00404A (es)
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
EA201690911A1 (ru) Соединения диметилбензойной кислоты
BR112017008176A2 (pt) método de preparação do carbonato de ácido glicérico.
EA201790800A1 (ru) Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа
AU2014230812A8 (en) Process for making benzoxazepin compounds
EA201690894A1 (ru) Феноксиэтилы
MX2019013816A (es) Compuesto usado como regulador de la autofagia, metodo de preparacion y sus usos.
EA201891769A1 (ru) СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ ПИРРОЛО[3,2-d]ПИРИМИДИНА И ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
ECSP22021103A (es) Sal
MX2016001144A (es) Derivado de pirazolilpirazol sustituido y uso del mismo como herbicida.
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
PH12016500109A1 (en) Substituted pyrazolylpyrazole derivative and use of same as herbicide
JOP20200030A1 (ar) مركب خماسي الحلقة
PH12016500110A1 (en) Substituted pyrazolylpyrazole derivative and use of same as herbicide
BR112015029399A2 (pt) produção em etapa única de uma composição de polipropileno
AU2016351424A8 (en) Pyranodipyridine compound
MX2015011375A (es) Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1].
BR112015031572A2 (pt) novo processo para a manutenção de uma razão de isômeros de compostos carotenoides
CL2017002148A1 (es) Derivados de tetrahidropiranil benzamida